T. Rowe Price Associates
NMRA icon

T. Rowe Price Associates’s Neumora Therapeutics NMRA Stock Holding History

T. Rowe Price Associates’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Buy
+84,155
New +$160K ﹤0.01% 3088
2025
Q2 		– Sell
-32,548
Closed -$33K – 3120
2025
Q1 		$33K Hold
32,548
– – ﹤0.01% 2976
2024
Q4 		$346K Sell
32,548
-592,930
-95% -$7.11M ﹤0.01% 2446
2024
Q3 		$8.26M Sell
625,478
-44,008
-7% -$513K ﹤0.01% 1177
2024
Q2 		$6.58M Sell
669,486
-83,438
-11% -$863K ﹤0.01% 1174
2024
Q1 		$10.4M Buy
+752,924
New +$12.2M ﹤0.01% 1102

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

T. Rowe Price Associates's NMRA Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 84,155 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #3088 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in NMRA as recently as Q1 2025.

T. Rowe Price Associates first reported a position in NMRA in Q1 2024 and has held it in 6 quarters since. The position peaked at $10.4M in Q1 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • T. Rowe Price Associates held 84,155 shares of Neumora Therapeutics worth $144K as of Q2 2026.
  • Neumora Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3088 holding.
  • T. Rowe Price Associates first reported a position in Neumora Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • T. Rowe Price Associates's Neumora Therapeutics position peaked at $10.4M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.